Before Key Meeting, FDA Stresses Risks of Novartis CAR-T Cancer Therapy – Xconomy
Xconomy |
Before Key Meeting, FDA Stresses Risks of Novartis CAR–T Cancer Therapy
Xconomy If approved for kids and young adults with acute lymphoblastic leukemia, or ALL, it would likely be the first so-called CAR-T medicine to reach the market. The field has faced years of intense scrutiny and questions about whether a patient's own T … Safety issues for Novartis CAR–T therapy main focus of FDA |
